Compare TG Therapeutics Inc (TGTX) vs Utilities Select Sector SPDR Fund (XLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Utilities Select Sector SPDR Fund — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while Utilities Select Sector SPDR Fund trades at $43.86. The key difference: TG Therapeutics Inc is trading nearer its 52-week high, Utilities Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| TGTX | XLU | |
|---|---|---|
Market Cap | $7.64B | — |
Sector | Health | — |
52-Week High | $59.06 | $47.73 |
52-Week Low | $26.94 | $41.31 |
Enterprise Value | $7.84B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
XLU, the Utilities Select Sector SPDR Fund, trades at $43.85, up 1.65% on the day, but technical indicators signal a bearish trend with moving averages showing strong sell signals. The ETF is positioned to benefit from AI-driven power demand, with recent news highlighting increased call option activity and its role as a defensive income play with a dividend scheduled for June 2026. However, key financial ratios like P/E and ROE are unavailable from the provided data.
The outlook for XLU is mixed; AI power demand offers growth potential, but technical weakness and lack of current fundamental metrics pose risks. Investors should weigh the defensive income characteristics against bearish technical signals and evolving sector dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →
